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Human diseases such as spina bifida are caused by a failure in cell morphogenesis and tissue 
fusion.  Dorsal closure in the Drosophila embryo is a model for these tissue closure processes 
where proper Jun N-terminal Kinase (JNK) signaling is necessary.  JNK activity is required in 
the leading edge cells of the epithelial layer to modulate the cytoskeleton and cell shape, 
allowing the epidermis to close on the dorsal side of the embryo.  The mixed lineage kinase 
(MLK), Slipper (Slpr), is the JNKKK which is responsible for activation of the pathway during 
dorsal closure.  The pathway components that regulate Slpr, as well as upstream activation 
signals, are not yet identified.  We have examined the involvement of the Ste20-like kinase 
Misshapen (Msn) to act as the JNKKKK in the JNK pathway during dorsal closure through a 
direct interaction between Msn and Slpr.  By observing phenotypes of recombinant and 
heterozygous mutants of slpr and msn, we have examined the genetic interactions. Also, by using 
a non-biased screen, we have investigated unknown regulators of the Slpr-mediated JNK 
pathway which have an effect on dorsal closure.  These techniques have begun to identify 
regulatory interactions of molecules within the JNK pathway, and have narrowed down regions 
of chromosome two which may contain new modifiers further regulating JNK signaling, in order 
to provide a robust and highly regulated tissue closure event.   
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1.0  CHAPTER 1: INTRODUCTION 
  
Everyday, researchers work diligently to uncover the mysteries behind many types of human 
maladies.  Their goal is to understand how specific biological processes function in order to 
design treatments and therapies for those affected.  The work described here is broadly focused 
on the cellular processes linked to spina bifida, cleft palate and defects in other developmental 
processes[1-4].  There are a limited number of active pathways during development which are 
responsible for proper patterning and maturation of the embryo[5].  Specificity is the key to 
regulating the signaling process, ensuring appropriate downstream outputs.  So how is one 
pathway able to elicit multiple responses?  Overlapping pathways or molecules with 
promiscuous activity in more then one pathway may be partly responsible.  It is also possible to 
modify core proteins in such a way as to cause a variety of responses.  Understanding the 
regulation of developmental pathways is necessary to find treatments for those afflicted by such 
early morphogenetic deficiencies.  
1.1 CELL SIGNALING 
The cell is a highly complex system receiving a barrage of signals and activities in order to 
operate as part of a tissue, a system, an organism.  There are a limited number of signaling 
pathways which are responsible for controlling development.  Because multiple signals activate 
each pathway, the ability to render distinct and diverse outputs based on efficient signaling 
depends a great deal on specificity.  Determining the mechanisms by which cells mediate this 
specificity is the key to understanding complex cell behaviors.   Multiple ligands may be used to 
coordinate specificity. This is clearly seen in the different Pvf ligands which may form homo- or 
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heterodimers to bind to a single Pvr receptor[6, 7].  Ligand dimerization and receptor activation 
can lead to actin reorganization, prevention of apoptosis or cell growth[6].  Another way 
pathways achieve multiple outputs could be through homologous family members.  Frequently, 
the core pathway may include one or more proteins which may act at a certain step in the 
pathway, and this may allow for more specific signaling[1, 8-14].  Further still, scaffolding 
proteins, branched pathways and multiple transcriptional regulators can all influence the outcome 
of a “single” signaling pathway[1, 8-12, 15-20].   
1.2 MAPK PATHWAY 
One pathway which controls many types of cell responses is the Mitogen-Activated Protein 
Kinase (MAPK) pathway.  This pathway plays a role in the regulation of embryogenesis, cell 
proliferation, cell differentiation and cell death[10].  Activation of the pathway is completed 
through a series of phosphorylation events beginning with stimulation of a triple kinase, the 
MAPKK kinase.  This in turn activates one or more MAPK kinases, which are duel specificity 
kinases, meaning they will consequently activate MAP kinases by phosphorylating specific Tyr 
and Thr residues[2, 8, 10, 12, 21].  This general schematic is seen in two types of MAPK 
pathways: the ERK (extracellular-signal related kinase) pathway, involving Ras/Raf/MEK/ERK 
and the Jun-N-terminal Kinase pathway, or the JNK pathway[22].  In Drosophila, the ERK 
pathway is involved in cell differentiation, proliferation and cell cycle progression[23], while the 
JNK pathway shows activity during embryogenesis, wound healing, and plays a role in immunity 
and cell cycle control[1, 9, 11-14, 22, 24].  This is a classic example of one core pathway having 
multiple outcomes.  Importantly, this pathway is conserved from yeast to metazoans. 
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Figure 1: Pathways. 
A schematic of the generic MAPK and JNK pathways, and the specific proteins responsible for 
JNK activation during dorsal closure.  Slpr is the triple kinase involved in dorsal closure.  
 
1.2.1 JNK Pathway 
The JNK pathway is activated in many types of cells to control many processes during 
development.  Similar to the mammalian stress-activated protein kinase (SAPK) pathway, the 
JNK pathway has been shown to regulate cell proliferation[25] and differentiation[26], immune 
response[27, 28], cell morphogenesis[24, 29], planar cell polarity[30, 31], cell death[26, 32] and 
wound healing[33, 34].  In Drosophila, the core signaling molecules include the JNKK 
Hemipterous (Hep)[35].  Hep activates the single kinase, Basket (Bsk), and Bsk in turn activates 
Jun.  Together with Fos, these two proteins make up the AP-1 transcription factor which is 
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activated in the majority of processes regulated by the JNK pathway[36].  This core of the JNK 
pathway transmits signals initiated from all upstream components. 
1.2.2 Triple Kinases 
There are six JNKK kinases (JNKKK) which can lead to explicit responses downstream.  Each 
triple kinase in Drosophila is a homolog of each MAPKKK family in mammalian cells which 
can be activated via a variety of upstream activation signals.  Family members include ASK, 
DLK, MLK, TAK, ZPK, and MEKK1-4(reviewed in[4].  In Drosophila, activation of ASK or 
TAK stimulates the JNK pathway during apoptosis and immunity responses[37, 38].  DLK is 
involved in cell differentiation and nervous system development in mice[39, 40].  Other 
JNKKK’s have been implicated in response to various signals such as LPS and oxidative 
stresses.  Mammalian MLKs are implicated in eyelid closure and neuronal apoptosis and the 
Drosophila MLK is required for dorsal closure[4, 9].   
1.2.3 Dorsal Closure 
This work focuses on dorsal closure and the activity of the Drosophila MLK, Slipper (Slpr), 
during this process.  During development of the fly embryo, germband extension and retraction 
take place after gastrulation, leaving an open hole on the dorsal side of the embryo.  A thin sheet 
of cells called the amnioserosa is left covering the developing embryo[41].  The sides of the 
epithelium must then be drawn together at the dorsal midline to form a seamless epithelial sheet.  
In order for dorsal closure to properly occur, JNK signaling is necessary in the leading edge cells 
of the ectodermal epithelial layer.  This causes the cells to elongate and accumulate considerable 
amounts of actin and myosin, which form a cable-like structure to act as a “purse-string.” The 
actin cord then pulls the two outer layers of cells toward the dorsal midline[3, 42].  The cells also 
develop filopodia and begin to pull themselves toward each other[43, 44].  The amnioserosa 
contracts to help pull the epithelial sheets closer and then deteriorates underneath while the cells 
fuse to form a seamless dorsal ectoderm.   
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1.2.1 Dpp and Puc: Two JNK pathway targets 
Two genes whose expression within the leading edge cells is dependent upon the JNK cascade 
are decapentaplegic (dpp) and puckered (puc)[45, 46].  Both genes are transcriptionally activated 
by the AP-1 transcription factor.  Dpp is a homolog of the TGF-ß family member BMP4 which 
activates Wingless (Wg) signaling[47].  Puc is a MAPK phosphatase which feeds back to 
negatively regulate the pathway by dephosphorylating Bsk[45].  Both proteins are upregulated in 
the leading edge cells as a result of JNK signaling.  Loss of Puc function causes excessive JNK 
signal [45], and a puckered midline along the dorsal side of the embryo, reflecting an inability of 
the JNK pathway to be downregulated.  Dpp and Puc expression are both useful reporters of JNK 
signaling in the leading edge.  
1.2.2 Slipper 
The JNKKK which activates Hep during dorsal closure is the Drosophila mixed lineage kinase, 
Slipper (Slpr)[13].  Slpr is the only MLK homolog in the fly, and so far the only triple kinase 
shown to be involved in dorsal closure[9, 13].  Mutant forms of slpr cause a loss of Dpp in the 
leading edge cells of the ectoderm mimicking the effect observed with mutations in hep and bsk.  
Furthermore, removing one copy of the JNK phosphatase puc can dominantly mask the effect of 
slpr mutant alleles[13].  Defects in the mammalian MLK3 cause epidermal defects at the dorsal 
midline of mice, although the mechanism behind this deficiency is not yet clear[48].  Upstream 
activators of Slpr are as yet unknown, but these and other studies show definitively Slpr’s role in 
dorsal closure. 
1.2.3    Slpr structure 
MLKs are termed as such because of the conservation in amino acids within the kinase domain 
which is common to both serine/threonine kinases and tyrosine kinases.  Their protein structure 
is characterized by an N-terminal Src-homology 3 (SH3) domain, followed by a kinase domain, a 
leucine zipper domain (LZ) and a Cdc42-Rac interacting binding (CRIB) motif[4, 9].  
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Mammalian homologs of Slpr have been shown to interact through this last domain with the 
Rho-family GTPase Rac[13, 49].  The LZ is necessary for dimerization and auto-
phosphorylation in the mammalian MLK3 while the SH3 is necessary for auto-inhibition through 
association with a conserved proline residue between the LZ and CRIB domains[9].  The active 
(open) form of Slpr may use the SH3 domain for binding proline-rich domains of an upstream 
activator[50].  The non-conserved C-terminus may be involved in signaling specificity.   
1.2.3.1 Slpr alleles 
 
There are currently three alleles of slpr which provide some insight into Slpr’s role within the 
JNK pathway.  The most severe allele is slpr921, which contains a point mutation in the kinase 
region making this allele an inactive form of Slpr.  Flies hemizygous for this allele die early in 
embryogenesis.  A second allele, slpr3P5, is an early truncation of the protein near the end of the 
kinase domain which allows some flies to live to the larval stages, although most still do not 
make it through embryogenesis and show dorsal open phenotypes.  Embryonic lethality 
associated with these alleles seems to be caused by a dominant-negative effect of the mutant 
proteins.  The null allele, slprBS06, is surprising in the fact that its phenotype is not as severe as 
our other alleles, allowing some flies to eclose as adults at a reproducible ratio.  slpr is a 
maternally deposited gene and it is believed that this contribution is enough to get some slprBS06 
embryos through the process of dorsal closure.  Some adult escapers possess a variety of 
phenotypes including missing maxillary palps, cleft thoraces, wrinkled wings, and genital 
rotation and eversion defects in males[51].  
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Figure 2:  Slpr alleles.   
Wild-type Slpr has four conserved domains, and a proline-rich region thought to be involved in 
auto-regulation.  Slpr921 is a kinase dead allele.  Slpr3P5 is a truncation mutant at the end of the 
kinase domain and SlprBS06 is a very early truncation and acts as a null allele.   
 
 
 
1.2.4 Misshapen 
Another gene which has been linked to dorsal closure and the JNK pathway is misshapen (msn).  
Msn is an Ste20-like kinase originally characterized for its role in photoreceptor axon targeting 
in the fly eye[52].  Of the two families of Ste20 kinases, Msn is in the SPS1 family, which is 
composed of kinases lacking a p21Rac- and Cdc42-binding (CRIB) domain in their amino 
terminus.  Mammalian members include germinal center kinase (GCK), NCK-interacting kinase 
(NIK) and hematopoietic progenitor kinase (HPK)[53].  In addition to its role in dorsal closure 
and photoreceptor shape control[52, 53], Msn is also involved in nuclear migration in the 
Drosophila eye[54] and acts downstream of the Frizzled receptor in planar cell polarity[30].  Su 
et al.,(1998), first showed an involvement for Msn in dorsal closure by looking at genetic 
interactions.  Expression of Msn in cell culture shows an upregulation of Jun; consistent with that 
observation, a dominant negative form of Msn inhibits Jun activation.  Embryos homozygous for 
msn mutants or doubly heterozygous for msn and bsk display a defect in dorsal closure and lack 
Dpp expression in the leading edge[53].   Nevertheless, the direct substrate for Msn has yet to be 
defined.   
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 1.2.4.1    Msn Structure 
 
Msn contains only three domains: a kinase domain at the N-terminus, a C-terminal regulatory 
region and a proline-rich region at the center of the protein.  PXXP motifs like those found in 
Msn have been shown to bind to SH3 domains in other proteins[55-58]. This proline-rich region 
is now known to bind to the SH3 regions of Dreadlocks (Dock) during axon guidance in the 
eye[59].  Dock is, however, not required for Msn function during dorsal closure[18]. 
Interestingly, observations made during a structure-function analysis of Msn revealed that Msn 
constructs lacking the C-terminal domain only rescued 10% of msn mutants indicating a role for 
both the kinase and C-terminal regulatory domains in dorsal closure[18, 53].  
 
1.3 SIGNIFICANCE 
It is clear that although there have been many advances in organizing the role of JNK signaling 
during dorsal closure, there is still much work to do.  This project set out to look for effectors 
and upstream activators of the pathway and to dissect their direct relationship to Slpr.  The first 
question asked was “Are there proteins which modify Slpr-mediated JNK signaling?”  To answer 
this, a large-scale, non-biased genetic screen was done using Drosophila deficiency lines 
covering the second chromosome.  A phenotype-based secondary screen was used to verify 
potential interactors.  The second question addressed was whether Misshapen is an upstream 
kinase responsible for activating Slpr to elicit JNK signaling during dorsal closure.  Pull-down 
assays and phenotypic evaluations were used to test for interactions. 
Attempts to answer these questions allow us to begin to understand what type of 
regulation is occurring upstream of the pathway in order to elicit the specific responses necessary 
for completing dorsal closure.  Identifying unknown regulators of the pathway may uncover 
cross-talk between two pathways as well as putative proteins not previously linked to JNK 
activity.  It is the goal of the lab to uncover positive and negative regulators of JNK signaling 
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during dorsal closure and to understand how that differs from signaling during other JNK-
activated processes.   
The screen uncovered two regions of chromosome two which gave consistent phenotypic 
results.  Further research will be needed to narrow down the precise genes involved and to 
characterize an interaction with Slpr.  It will also be necessary to observe any defects in dorsal 
closure, or other JNK-dependent processes.   
Studies testing a direct interaction of Msn with Slpr did not lead to any definitive 
conclusions; however, progress was made providing the laboratory with various Msn constructs 
and protocols which can be used once reliable resources are available.  Phenotypic and 
biochemical assays have been established and may lead to identification of proteins with a direct 
effect on Slpr activation.   
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2.0    CHAPTER 2:   A GENETIC SCREEN FOR EFFECTORS OF SLPR-
MEDIATED JNK SIGNALING 
2.1 BACKGROUND AND SIGNIFICANCE 
It has recently been hypothesized that members of the ERK-mediated MAPK pathway 
may be involved in stimulation of the JNK pathway, or may play a role in compensatory 
signaling.  Embryos double mutant for slprBS06 and pvf1, a PDGF/VEGF ligand, have dorsal 
closure defects.  Also, mutant pvr/pvf1 receptor/ligand complexes have been shown to cause 
genital rotation defects, as seen in slprBS06 mutants[7].  One member of the ERK-mediated 
pathway, Pp2C is a serine/threonine phosphatase which has shown genetic interactions with the 
JNK signaling pathway as well(Stronach unpublished,[60]).  Such examples of cross talk 
between pathways have more recently come to light[59, 61-71], indicating that regulation of 
signaling is far more complex than single pathway relay events.   
It is logical then, to wonder if such a closely related pathway might be able to 
compensate for loss of the Slpr-mediated JNK signal, or if both pathways are part of the many 
signals which provide the cell with a balanced readout to ensure that dorsal closure takes place.  
Still, other proteins may exist which may potentiate or attenuate the JNK signal and effect 
dosage or specificity of signaling modifications.  If such players exist but are not absolutely 
necessary for dorsal closure to take place, identifying them may not be so obvious.  
In addition to observations regarding the ERK/MAPK pathway, other mutants which 
shard phenotypic defects with Slpr potentially implicate them in JNK signaling pathway 
regulation.  It was previously stated that the slprBS06 allele lacks detectable protein production, 
but with the help of the maternal contribution allows some adults to survive.  Interestingly, the 
number of hemizygous slprBS06 males that eclose is consistently observed at 10% compared to 
their brothers[51].  Therefore, the question was raised “Are there other proteins which can 
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potentiate or attenuate the slprBS06 signal and consequently increase or decrease the number of 
adult males which eclose?”  By reducing the dosage of genes using deficiencies and observing 
phenotypic changes, we have found a way to look for modifiers of the JNK pathway.  
2.1.1 Hypothesis:  Modifying the dosage of proteins involved in regulating Slpr-mediated 
processes or molecules acting in parallel pathways which affect tissue morphogenesis may 
alter the phenotypes observed in slpr mutants. 
2.2  EXPERIMENTAL APPROACHES 
The Bloomington Deficiency kit was used to remove generous portions of the second 
chromosome.  It was hypothesized that removing one copy of a gene which had some effect on 
the Slpr-mediated pathway, would affect the amount of JNK signaling and therefore cause a 
change in the number of slprBS06 males which eclosed.  There were originally 73 deficiency lines 
tested which covered most of the second chromosome.  Expectations included finding known 
members of the pathway as well as novel modifiers of JNK signaling during dorsal closure. 
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Figure 3: Deficiency cross outline.  
Df flies were crossed to slprBS06 flies and the number of males was scored.  The percent viable 
was measured as slprBS06;Df males over FM7i;Df males.  FM7i and the w- marker were used to 
decipher between the two classes of Df-carrying flies.  “Bal” stands for the balancer over which 
the Df was stabilized.  
 
 
2.2.1 Set up of cross 
   The original screening process looked at progeny from deficiency lines which remove 
large regions of the second chromosome, crossed to slprBS06 mutant lines.  The F1 male progeny 
were scored, with the genotypes indicated as a percentage.  Normally, 10% of the male progeny 
with the slprBS06 allele eclose as adults.  I chose ≥ 50% eclosion or ≤ 2% eclosion to define 
putative suppressors or enhancers, respectively.  
 
 
2.2.2 Results of large deficiencies 
Table 1:  Deficiency lines from initial screen which alter the number of BS06 males.   
w,slprBS06/FM7i females were crossed to Df/Bal males.  The stocks listed here by breakpoints 
made the first cut by producing more than 50% or less than 2% w,slprBS06;Df males (compared to 
FM7i;Df males).   *stocks were sick and did not produce many progeny; analyzed with caution   
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 Breakpoints Df stock # Deficiency %BS06;Df #BS06;Df #FM7i;Df
21D1-2;22B2-3 3084 Df(2L)last2 0.0% 0 30 
22D2-3;22F1-2 7144 Df(2L)BSC37 87.50% 14 16 
23C1-2;23E1-2 1567 Df(2L)JS17,dpp[d-ho] 50.0% 9 18 
23C5-D1;23E2 6875 Df(2L)BSC28 181.25% 29 16 
23E5;23F4-5 6965 Df(2L)BSC31,net[1]cn[1] 64.71% 11 17 
25D2-4;26B2-5 781* Df(2L)cl-h3 0.0% 0 6 
25F3-26A1;26D3-11 490 Df(2L)E110 50.0% 15 30 
29C1-2;30C8-9 2892* Df(2L)N22-14 0.0% 0 6 
32F1-3;33F1-2 3079* Df(2L)PrI,PrI[1]nub[PrI] 100.0% 7 7 
34A3;34B7-9 6999* Df(2L)BSC30 50.00% 2 4 
34B12-C1;35B10-C1 3138* Df(2L)b87e25 100.0% 2 2 
35B4-6;35F1-7 3588 
Df(2L)TE35BC-
24.b[1]pr[1]pk[1]cn[1]sp[1] 0.0% 0 25 
36C2-4;37B9-C1 420* Df(2L)TW137, cn[1]bw[1] 0.0% 0 1 
42A1-2;42E6-F1 1007 Df(2R)nap9 0.0% 0 23 
42A2-3;58A4, h42-
h43;59E1 749 In(2R)bw[VDe2L]Cy[R] 0.0% 0 18 
49A4-13;49E7-F1 754 Df(2R)vg-C 52.0% 13 25 
51D3-8;52F5-9 3518 Df(2R)Jp1 133.3% 12 9 
54B17-C4;54C1-4 5680 Df(2R)robl-c 71.4% 25 35 
55A;55F 1547* Df(2R)PC4 0.0% 0 11 
56D7-E3;56F9-12 6647 Df(2R)BSC22 0.00% 0 18 
56F12-14;57A4 6609 Df(2R)BSC19,cn[1]bw[1] 56.0% 14 25 
58D1-2;59A 282 Df(2R)X58-12 76.9% 10 13 
60E6-8;60F1-2 3157 Df(2R)ES1,b[1]pr[1]cn[1]wx[wxt] 87.0% 20 23 
60F1;60F5 4961 DF92R)Kr10,b[1]pr[1]Bl[1]c[1] 60.0% 6 10 
 
 
 
The stocks in Table 1 showed ≥50% or 0% slprBS06 males after one round of scoring.  New 
deficiencies removing overlapping regions still within the original chromosomal area defined by 
the defiencies were tested in a similar fashion for suppression or enhancement of the slprBS06 
phenotype.  This data is shown in Table 2.  The stocks in Table 1 are listed as “Parental Dfs” to 
compare the percentages of slprBS06 males eclosing between the two different sized deficiencies.   
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2.2.3 Results of overlapping deficiencies 
Table 2:  Overlapping deficiency regions.   
These stocks were tested because they were smaller, overlapping regions of the deficiencies from 
Table 1.  These were scored in the same way.  "Parental" stands for the larger deficiency (from 
Table 1) encompassing the same chromosomal region.  Stocks producing a similar amount of 
w,slprBS06 males would help to narrow down the gene which was presumably affecting the 
pathway.  *stocks were sick and produced low numbers; noted with caution 
 
Breakpoints Df %BS06;Df BS06;Df FM7;Df Breakpoints
Parental 
Df
Parental 
%
  W1118 14.0% 6 43   W1118 5.0% 
21D2;21D3 7489 42.1% 8 19 21D1-2;22B2-3 3084 0.0% 
21D3;21E3 7490* 50.0% 2 4 21D1-2;22B2-3 3084 0.0% 
22A3;22B3 5450 15.4% 2 13 21D1-2;22B2-3 3084 0.0% 
22D1;22E1 7493 5.6% 1 18 23C5-D1;23E2 6875 181.2% 
22E1;22F3 7783* 0.0% 0 0 23C5-D1;23E2 6875 181.3% 
23C4;23D1 7784 6.9% 2 29 23C5-D1;23E2 6875 181.3% 
23D2;23E3 4954 22.7% 5 22 23C5-D1;23E2 6875 181.3% 
23E5;23F5 7787 6.7% 1 15 23E5;23F4-5 6965 64.7% 
34A2;34A7 7823* 0.0% 0 3 36C2-4;37B9-C1 420 0.0% 
34A4;34B6 7421 183.3% 11 6 34A3;34B7-9 6999 50.0% 
36C;36E-F 6087 31.6% 6 19 36C2-4;37B9-C1 420 0.0% 
36E6-F1;36F7-
9 343* 100.0% 7 7 36C2-4;37B9-C1 420 0.0% 
36F7-9;37B2-7 3781* 20.0% 2 10 36C2-4;37B9-C1 420 0.0% 
 37B2-8;37C5 5372 7.1% 2 28 36C2-4;37B9-C1 420 0.0% 
41A;41A 742 14.3% 4 28 
42A2-3;58A4, h42-
h43;59E1 749 0.0% 
41BC;42A16-
B1 4308* 0.0% 0 7 
42A2-3;58A4, h42-
h43;59E1 749 0.0% 
56C4;56D6-10 6866 14.3% 2 14 56D7-E3;56F9-12 6647 0.0% 
58B3;59A1 100* 500.0% 5 1 
42A2-3;58A4, h42-
h43;59E1 749 0.0% 
59C1;59C4 7265 7.1% 1 14 
42A2-3;58A4, h42-
h43;59E1 749 0.0% 
59C3-4;59D1-2 6147* 14.3% 1 7 
42A2-3;58A4, h42-
h43;59E1 749 0.0% 
 
 
 
The stocks in both Tables 1 and 2 were retested for accuracy and consistency.   There were some 
stocks which produced offspring with phenotypes uncharacteristic of the known chromosomal 
markers and were unable to be classified. This was attributed to possible recombination, 
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nondisjunction or incorrect notation of chromosomal markers.  These lines were not dissected 
further. Some stocks were very sick and were not able to give more than 15 male progeny, even 
though hundreds of female progeny eclosed.  In order to get a more confident percentage and 
still retain the ease of using deficiencies for screening, we then retested some crosses using a 
stock of y,w,slprBS06 flies, utilizing the yellow body marker. Data from all tables plus the data 
from the second set of crosses was put into Table 3 as a total collection of all scored flies.  Figure 
3 is a graphical representation of all flies scored. From here, stocks which produced consistent 
results were deemed significant.  The break points were analyzed for two reasons: (1) to obtain 
smaller deficiencies for further analysis and (2) to look for specific genes which could be tested 
directly for an interaction.   
2.2.4 Total deficiency data results 
 
Table 3: Total deficiency data.  
73 Df lines were crossed to w,slprBS06/FM7i  or y,w,slprBS06/FM7i flies and slprBS06;Df males 
were compared to FM7i;Df males.  Some stocks were very difficult to score based on phenotype 
or were too sick to produce enough progeny for confident analysis and were thrown out.  * marks 
stocks determined to be significant, + marks stocks with too few male progeny, or undetermined 
genotypes 
 
Breakpoints
Stock 
number Deficiency Name
%slplrBS06/FM7 
(Df)
#slprBS06;Df 
scored
#FM7i;Df 
scored
  W1118 None, wild type control 10.34% 66 638 
21C3-4;21C6-8 6608 Df(2L)BSC16,net[1]cn[1] 14.29% 3 21 
21D1-2;22B2-3 3084* Df(2L)last2 1.79% 1 56 
21D2;21D3 7489 Df(2L)Exel6002,P{w[+mC}=XP-u}Exel6002 22.45% 11 49 
21D3;21E3 7490 Df(2L)Exel6003,P{w[+mC}=XP-u}Exel6003 11.54% 6 52 
22A3;22B3 5450+
Df(2L)frtz14,P[ry[+t7.2]=neoFRT}42D 
cn[1]sp[1] 15.4% 2 13 
22D1;22E1 7493 Df(2L)Exel6007,P{w[+mC}=XP-u}Exel6007 5.26% 2 38 
22D2-3;22F1-2 7144* Df(2L)BSC37 34.72% 25 72 
22E1;22F3 7783+ Df(2L)Exel7011,P+PBac{XP5.WH5}Exel7001 0.00% 0 6 
23C1-2;23E1-2 1567* Df(2L)JS17,dpp[d-ho] 40.00% 12 30 
23C4;23D1 7784 Df(2L)Exel7014,P+PBac{XP5.RB3}Exel7014 5.26% 2 38 
23C5-D1;23E2 6875+ Df(2L)BSC28 32.14% 36 112 
23D2;23E3 4954 Df(2L)S2590 22.7% 5 22 
23E5;23F4-5 6965* Df(2L)BSC31,net[1]cn[1] 37.80% 31 82 
23E5;23F5 7787 Df(2L)Exel7016,P+PBac{XP5.WH5}Exel7016 17.92% 19 106 
23F3-4;24A1-2 6507+ Df(2L)drm-P2,p{w[+mC]=lacW}Pdsw[k10101] 16.67% 2 12 
24A2;24D4 5330+ Df(2L)ed1 30.77% 4 13 
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Table 3 continued… 
 
25D2-4;26B2-5 781+ Df(2L)cl-h3 83.33% 5 6 
25F3-26A1;26D3-11 490* Df(2L)E110 40.79% 31 76 
26D10-E1;27C1 6374 Df(2L)BSC7 15.79% 3 19 
27C1-2;28A 2414 Df(2L)spd[j2],wg[spd-j2] 10.34% 6 58 
27E2;28D1 4956+ Df(2L)XE-3801 22.22% 2 9 
28A4-B1;28D3-9 7147+ Df(2L)BSC41, dp[ov1] cn[1] 15.38% 2 13 
28DE 140 Df(2L)Trf-C6R3 6.35% 4 63 
28E4-7;29B2-C1 179 Df(2L)TE29Aa-11, dp[*] 5.77% 3 52 
29C1-2;30C8-9 2892+ Df(2L)N22-14, (Raw Df) 10.00% 2 20 
30C3-5;30F1 6478 Df(2L)BSC17 10.00% 2 20 
30D-F;31F 1045+ Df(2L)Mdh,cn[1]/Dp(2;2),cn[1] N/A 
Hard to 
score -- 
31B;32A 3366+ Df(2L)J2 (bsk Df) 42.86% 6 14 
32D1;32D4-E1 7143 Df(2L)BSC36 15.38% 4 26 
32F1-3;33F1-2 3079* Df(2L)PrI,PrI[1]nub[PrI] 87.27% 48 55 
34A2;34A7 7823 
Df(2L)Exel7055,P+ 
PBac{XP5.WH5}Exel7055 7.98% 15 188 
34A3;34B7-9 6999+ Df(2L)BSC30 27.66% 26 94 
34A4;34B6 7421 
Df(2L)ED784, P{w+[mW.Scer 
/FRT.hs3]=3'.RS5+3.3'}ED784 37.93% 11 29 
34B12-C1;35B10-C1 3138+ Df(2L)b87e25 28.57% 2 7 
35B4-6;35F1-7 3588* Df(2L)TE35BC-24.b[1]pr[1]pk[1]cn[1]sp[1] 1.28% 1 78 
35D1;36A6-7 1491 Df(2R)r10,cn[1] 10.00% 2 20 
36C;36E-F 6087 Df(2L)T317,b[1],pr[1],cn[1],sca[1] 17.24% 5 29 
36C2-4;37B9-C1 420+ Df(2L)TW137, cn[1]bw[1] 2150.00% 43 2 
36E6-F1;36F7-9 343+ Df(2L)M36F-s6 46.67% 7 15 
36F7-9;37B2-7 3781+ Df(2L)TW3,l(2)74i[1] 20.00% 2 10 
37B2-12;38D2-5 567 Df(2L)pr-A16,cn[1]bw[1] 9.46% 7 74 
 37B2-8;37C5 5372+ Df(2L)hk-UC2 21.43% 3 14 
38A6-B1;40A4-B1 167 Df(2L)TW161, cn[1]bw[1] 14.93% 10 67 
40h35;40h38L 4959+ Df(2L)C' 50.00% 13 26 
41A;41A 739 Df(2R)M41A4 45.00% 9 20 
41A;41A 742 
Df(2R)rl10a,lt[1],rl[10a],cn[1]/ 
In(2LR)bw[v1],ds[33k]bw[v1] 12.20% 5 41 
41BC;42A16-B1 4308 Df(2R)nan14 1.35% 1 74 
42A1-2;42E6-F1 1007* Df(2R)nap9/In(2LR)Gla 20.00% 7 35 
42A2-3;58A4, h42-
h43;59E1 749* 
In(2R)bw[VDe2L]Cy[R]/ 
In(2LR)Gla,wg[Gla-1] 0.00% 0 60 
42B3-5;43E15-18 1888 Df(2R)ST1,Adh[n5]pr[1]cn[*] 15.00% 6 40 
42E;44C 3368+ Df(2R)cn9 10.00% 1 10 
43F;44D3-8 198 Df(2R)H3C1 16.67% 4 24 
44D1-4;44V12 201 Df(2R)H3E1 4.55% 1 22 
44F10;45D9-E1 3591+ Df(2R)Np5,In(2LR)w45-32n,cn[1] 21.43% 3 14 
45A6-7;45E2-3 4966 Df(2R)w45-30n,cn[1] 8.33% 3 36 
45D3-4;45F2-6 6917+ Df(2R)BSC29,cn[1]bw[1]sp[1] 23.08% 9 39 
46A;46C 1743+ Df(2R)B5,px[1]sp[1] 7.69% 1 13 
46C2;47A1 1702+ Df(2R)X1,Mef2[X1] 30.77% 4 13 
46D7-9;47F15-16 447+
Df(2R)stan1,P{ry[+t7.2]= 
neoFRT}42Dcn[1]sp[1] 71.43% 5 7 
47D3;48B2 190 Df(2R)en-A 34.00% 17 50 
48A3;48C6-8 1145 Df(2R)en30 3.90% 3 77 
48C5-D1;48D5-E1 7145 Df(2R)BSC40 40.00% 6 15 
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Table 3 continued… 
 
48E;49A 4960+ Df(2R)CB21 36.36% 4 11 
48E1-2;48E2-10 7146+ Df(2R)BSC40 13.33% 2 15 
48E12-F4;49A11-B6 5879 
Df(2R)BSC3,w[+mC]unch[k15501] 
cn[1]bw[1]sp[1] 8.70% 2 23 
49A4-13;49E7-F1 754* Df(2R)vg-C 41.18% 14 34 
49C1-4;50C23-D2 442+ Df(2R)CX1,b[1]pr[1] 28.57% 2 7 
50D1;50D2-7 6516+ Df(2R)BSC18 27.27% 3 11 
50E6-F1;51E2-4 6455+ Df(2R)BSC11 7.69% 1 13 
51D3-8;52F5-9 3518+ Df(2R)Jp1 33.93% 19 56 
52F5-9;52F10-53A1 3520+ Df(2R)Jp8,w[+] 18.18% 2 11 
53E;53F11 6404 Df(2R)P803-Delta15,cn[1] 17.65% 6 34 
53E4;53F8 6916+
Df(2R)ED1,P{w[+mW.Scer/ 
FRT.Hhs3]=3'.RS5+3.3'}ED1 7.69% 1 13 
54B17-C4;54C1-4 5680* Df(2R)robl-c 31.33% 26 83 
54C1-4;54C1-4(?) 5574 
Df(2R)k10408,P{w[+mC]= 
acW}mthl3[k10408] 10.14% 7 69 
54D1-2;54E5-7 6779 Df(2R)14H10Y-53 22.22% 4 18 
54E5-7;55B5-7 6780+ Df(2R)14H10-35 15.38% 2 13 
55A;55F 1547+ Df(2R)PC4 4.35% 1 23 
55E2-4;56C1-11 757 Df(2R)P34 5.56% 4 72 
56C4;56D6-10 6866 Df(2R)BSC26 6.35% 4 63 
56D7-E3;56F9-12 6647 Df(2R)BSC22 11.54% 3 26 
56F12-14;57A4 6609 Df(2R)BSC19,cn[1]bw[1] 19.72% 28 142 
56F5;56F15 543 Df(2R)017 47.06% 8 17 
56F9-17;57D11-
12,56D-E;58E-F 3467 Df(2R)AA21,c[1]px[1]sp[1] 8.57% 3 35 
58B3;59A1 100+ Df(2R)X58-8,pr[1],cn[1] 14.29% 1 7 
58D1-2;59A 282+ Df(2R)X58-12 65.22% 30 46 
59A1-3;59D1-4 3909 Dr(2R)59AD 5.00% 1 20 
59C1;59C4 7265 Df(2R)Frd-R1,wg[Sp-1],Pin[2] 5.13% 2 39 
59C3-4;59D1-2 6147 Df(2R)twi,b[1],pr[1],cn[1],bw[1] 6.90% 2 29 
59D5-10;60B3-8 1682 Df(2R)or-BR6 16.00% 4 25 
60E2-3;60E11-12 2471 Df(2R)M60E/In(2LR)bw[V32g],bw[V32g] 8.11% 3 37 
60E6-8;60F1-2 3157* Df(2R)ES1,b[1]pr[1]cn[1]wx[wxt] 32.09% 43 134 
60F1;60F5 4961+ DF(2R)Kr10,b[1]pr[1]Bl[1]c[1] 60.00% 6 10 
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Figure 4:  Graphical representation of results from total screen.   
The bar graph shows the percentages of slprBS06;Df males ranging from 0%-100%.  Deficiencies 
are labeled by stock number.  Maroon bars are greater than 50%.  The dark blue bar is the control 
(W1118) at 10%.   
 
2.2.5 Genes in smaller regions 
Once the final numbers of F1 progeny were tabulated (Table 3) and analyzed, stocks producing a 
significant change in male progeny were analyzed by breakpoints. Flybase 
(http://flybase.bio.indiana.edu/) was used to find deficiencies removing smaller regions of the 
second chromosome which overlapped with the previous lines.  These were then crossed again to 
y,w,slprBS06 flies and scored in the same manner.  Results are listed in Table 4.   
Also, two overlapping enhancer lines showing 0% slprBS06; Df males, both uncovered the 
kinase Src42A within the deleted region.  Src42A has been shown genetically to play some role 
in dorsal closure, indicated by defects observed in homozygous src42A or transheterozygous 
src42A tec29 or src42A src64 mutant embryos[72].  Therefore, it was hypothesized that Src42A 
was a probable attenuator of the slprBS06 signal.  Two src24A recessive, hypomorphic mutants 
were obtained; (1) src42Amyri a myristylation mutant, missing the second amino acid, and (2) 
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src42AE1, a stop codon eliminating the COOH-terminal part of the kinase domain[72].  These 
were also crossed to y,w,slprBS06 flies and scored correspondingly (Table 4).   
 
 
 
Table 4:  Overlapping Deficiency Stocks.   
Deficiencies which showed a significant change in the number of slpr  males were analyzed 
by breakpoints.  Deficiencies removing smaller regions of the overlapping deficiencies of the 
chromosome as well as two alleles of the src42A kinase were tested using y,w,slpr .  W1118 
was used as a control cross.
BS06
BS06
    * marks stocks causing a significant effect, + marks stocks with a 
significant but opposite effect as compared to the “parental” (larger) deficiency stock.  
 
Breakpoints Df Stock #
% 
BS06;Df
y,w,BS06; 
Df FM7i;Df Parental Breakpoints
Parental 
Df
Parental 
%
33A8-B1;33B2-
3 3129 47.0% 31 66 32F1-3;33F1-2 3079 87% 
33A1-2;33B1-2 3130 30.0% 18 60 32F1-3;33F1-2 3079 87% 
33B2-3;34A1-2 3344 16.1% 9 56 32F1-3;33F1-2 3079 87% 
35C2;35C5 3592 21.4% 9 42 35B4-6;35F1-7 3588 1% 
41F3-4;42A3-9 4913* 0.0% 0 53 41BC;42A16-B1 4308 1% 
32D1;32F1-3 5869+ 0.0% 0 64 32F1-3;33F1-2 3079 87% 
34C6-7;35B9-
C1 6068 14.3% 9 63 35B4-6;35F1-7 3588 1% 
35B1-2;35B2-
4+35D1-2;35E2 6085 12.2% 5 41 35B4-6;35F1-7 3588 1% 
35C5;35D2 7830* 1.4% 1 74 35B4-6;35F1-7 3588 1% 
42A13;42E6 8045 17.5% 7 40 
42A2-3;58A4, h42-
h43;59E1/41BC;42A16-
B1 749/4308 0% 
41D1-2;42A2-
10 8893 7.8% 4 51 41BC;42A16-B1 4308 1% 
42A7-10;42B1-
2 8896 6.3% 3 48 41BC;42A16-B1 4308 1% 
42A6-7 Src42AE1 4.5% 5 111 
42A2-3;58A4, h42-
h43;59E1 749 0% 
42A6-7 Src42Amyri 9.8% 4 41 
42A2-3;58A4, h42-
h43;59E1 749 0% 
  W1118 7.4% 4 54     10% 
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2.2.6 Conclusions 
The purpose of the screen was to pull out modifiers of the JNK pathway by removing one copy 
of genes on the second chromosome and observing an effect on the number of males with both 
the deficiency chromosome and the slprBS06 allele.  Starting with large deficiencies was 
beneficial in order to cover as much of the chromosome as possible with the least amount of 
work.  Known members of the JNK pathway, bsk and raw, both have allelic interactions with 
slprBS06, but deficiencies tested in this screen removing portions of these genes do not cause a 
significant effect, indicating the possibility to miss effectors. However, four of the smallest 
deficiencies analyzed show strong enhancement or suppression of the slprBS06 number of males.  
Three of those are enhancers.  The src42A alleles did not show any change in the number of 
slprBS06; Df males (at 4.5% for src42AE1 and 9.8% for src42Amryi).  Stronger alleles should be 
tested.  Also, examination of the results using the smaller deleted regions shows that one of the 
smaller deficiencies which was deemed significant did not give the same outcome (enhancement 
or suppression) as their “parental” deficiency.  This could be explained by the presence of two or 
more genes in the large deficiency which may affect one another, or together, may cause an 
effect on the JNK signal which is different from the effect of removal of only one of those genes.  
It may also be a result of different genetic backgrounds in which the deficiencies were generated.  
More thorough investigation and testing of available alleles will help to resolve this anomaly.  
2.3 GMR-RAC 
A secondary screen using an overexpression of the GTPase Rac (GMR-Rac[73]) in the fly eye 
was used to check the validity of our putative interacting stocks.  Overexpression of Rac using 
the eye-specific GMR driver leads to an upregulation of the JNK pathway and causes the eye to 
become smaller and darker. The ommatidia become unordered producing a “rough” appearance 
in the posterior portion of the eye.  When mutant alleles of the JNK pathway are crossed to this 
line, they reduce the amount of JNK signaling causing a repression of the phenotype – a normal 
looking eye.  Crossing GMR-Rac flies to mutants of the negative feedback regulator Puc 
hyperactivates the JNK pathway and causes enhancement of the phenotype, making the eyes 
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much smaller, darker and highly unordered[13]. Consequently, deficiency lines which enhanced 
the slprBS06 phenotype should suppress the rough eye phenotype seen here.  Lines which 
suppressed the slprBS06 lethality should enhance the eye phenotype.  All Df crosses were 
compared to crosses with wild-type flies, and to crosses with members of the known JNK 
signaling cascade 
 
 
 
 
Figure 5:  GMR-Rac eye phenotypes. 
GMR-Rac flies were crossed to deficiency stocks which had shown an effect on the number of 
slprBS06 male adults.  W1118 is wild-type, GMR-Rac shows the original rough eye phenotype.  
Bsk and slpr3P5 show how known members of the pathway suppress the phenotype and pucE69 
shows how a negative regulator enhances the phenotype (pictures adapted from Stronach 2002).  
Stock 3079 (Df(2L)PrI,PrI[1]nub[PrI], breakpoints 32F1-3;33F1-2) is an enhancer, and stock 
4308 (Df(2R)nan14, breakpoints 41BC;42A16-B1) is a suppressor.  Stocks 4913, 7830, 3588, 
749, and the Src42A alleles showed no significant change in the phenotype.   
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 2.3.1 Results 
Two of the deficiency stocks produced expected results when crossed to GMR-Rac flies.  3079 
was a suppressor of the slprBS06 phenotype, producing 87% BS06 males.  When screened using 
Rac overexpression, the eye phenotype was enhanced, indicating a negative regulatory 
relationship on the JNK signal.  Similarly, 4308 enhanced the BS06 phenotype, knocking down 
the number of BS06 males.  This line was able to repress the eye phenotype (like slpr mutants), 
indicating a requirement to promote signaling through the JNK pathway.  The consistent results 
strongly suggest that there are modifiers of Slpr-mediated JNK signaling within these regions of 
chromosome two. 
One line (stock 7830) produced curious results, enhancing both the BS06 and the GMR-
Rac phenotypes.  Also, stock 5869 enhanced BS06 but showed no effect on the GMR-Rac 
phenotype.  Its role in the pathway is questionable, but should still be analyzed further.  Both of 
these results are curious but because of the consistency of their results in the BS06 screen, they 
should be analyzed further. 
2.3.2 Conclusions 
The deficiency stocks ordered as a kit are useful for the type of non-biased screen that was done 
here.  The goal of the screen was to discover modifiers of JNK signaling and currently, there are 
two stocks which have produced consistent results in both screens, and three stocks which 
produce consistent numbers in the slprBS06 screen only.  A similar screen using the deficiency kit 
of the third chromosome has already produced a least one modifier of JNK signaling, the 
phosphatase Pp2C.  Clearly, the screen is able to meet expectations and the work described here 
has provided the lab with five possible enhancers or suppressors of the JNK pathway.  Future 
work should define the genes within the regions described and may lead to characterization of 
novel proteins and/or specific pathway interactions. 
As discussed previously, when planning the cross itself, it was beneficial to use multiple 
markers to ensure accurate results and to obtain high enough numbers to be confident with the 
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results.  It was also beneficial to set up multiple crosses to ensure consistent percentages.  This 
screen has revealed three lines which show consistent results in the slprBS06 viability screen 
throughout.  One of the small deficiencies is a strong candidate as an enhancer of the slprBS06 
phenotype, but is different from its larger, “parent” deficiency region.  Although the 
inconsistency is an issue, it is not unexplainable.  The larger deficiencies cover vast stretches of 
the chromosome and remove up to 100 genes; therefore, there may be unknown interactions 
occurring depending on the genes contained in the deficiency regions.  As a result, each of the 
smaller regions should be studied in depth to rule out multiple genetic interactions.   
The GMR-Rac screen is also useful as a secondary screen and is more phenotypically 
based rather than based on numbers of flies.  Indeed, this could also be used as a primary screen 
itself.  This data shows that two of the deficiency interactors act appropriately in the secondary 
screen, confirming the validity of the Df screen and providing further confidence that the region 
in question harbors a true modifier of the pathway.  Still, results which oppose the Df screen are 
not necessary unreliable, as the role the JNK pathway plays in Rac-dependent eye 
morphogenesis is currently unclear.  Similarly, if the molecule in question acts through another 
pathway, in an upstream role, or in a compensatory function, it may be unaffected by Rac 
overexpression.   
Testing of the src42A alleles showed no significant effect on the slprBS06 viability.  The 
overlapping region of the two deficiencies will need to be analyzed further to look for other 
potential modifiers.  Interestingly, this region is adjacent to the centromere and that might be the 
cause of the outcome observed.  Further testing is necessary.  
Overall the ability of both screens to identify suppressors or enhancers of the Slpr-
mediated JNK pathway was reasonable.  I improved several problematic issues by using more 
chromosomal markers and retesting Df lines.  More detailed analysis will be necessary to find 
the gene(s) causing the perceived effect. 
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Table 5: Genes of interest in slprBS06 modifying Dfs. 
 
Breakpoints Df # Df Name Genes of interest Effector Type Effector type
   deleted
(of BS06 
phen.)
(of Rac eye 
phen.)
h42-
h43;42A2-3 749 
In(2R)bw[VDe2L]
Cy[R] rl, Src42A Enhancer No change 
      
32F1-3; 
33F1-2 3079 Df(2L)Prl unknown Suppressor Enhancer 
      
41BC;42A16-
B1 4308 Df(2R)Nap14 
Src42A, p120ctn, 
Gprk1 Enhancer Suppressor 
      
32D1;32F1-3 5869 Df(2L)FCK-20 unknown Enhancer No change 
      
35C5;35D2 7830 Df(2L)Exel8034 unknown Enhancer No change 
 
2.4 FUTURE DIRECTIONS 
The next step would be to analyze the smaller deficiency regions of chromosome two to uncover 
the interactors.  Some potential genes of interest are listed in Table 5. Rl is the MAPK involved 
in photoreceptor eye differentiation[74], and more severe alleles of Src42A should be tested. 
P120ctn regulates in adherens junctions, which may influence cell movement[75].  Gprk1 is a G-
protein coupled receptor kinase[76]  There are a number of uncharacterized and/or predicted 
genes in most of the deleted regions which may lead to identification of new protein products.  
Available alleles of possible effectors should be tested individually in both screens.  Phenotypes 
of the slprBS06;Df males should also be noted since the phenotypic defects of slprBS06 males are 
numerous.   
GMR-Rac screening should be reanalyzed for consistency.  It is extremely important to 
use comparative analysis during this phenotypic study setting up crosses to wild-type flies and 
known enhancers and suppressors of Rac overexpression.  Also, stocks are sometimes unhealthy 
and should therefore be done in duplicate and scored everyday for reliable observation.  
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Furthermore, the GMR driver is temperature sensitive.  Analysis of putative modifiers at varying 
temperatures may be beneficial.    
If a known gene is recognized as an enhancer or suppressor through the previous 
screening processes, it can be tested in a variety of ways to show a direct interaction with the 
Slpr-mediated JNK signaling.  Protein overexpression and rescue experiments can be used to 
compare phenotypic effects and the presence of dorsal open cuticles.  Mutant alleles of other 
members of the JNK pathway (bsk, puc, etc.,) can be used to test for interactions with 
uncharacterized proteins as well.   If it is an uncharacterized gene that appears to modify the slpr-
mediated effect, then characterization will be necessary to look for homologs and similar 
structured proteins.  Also, protein production can be measured and analyzed for expression 
profiles using tagged forms of the protein and immunofluorescence.  
The large-scale screen used here was successful in identifying regions of the second 
chromosome that seemed to have an effect on Slpr-mediated JNK signaling.  The remarkably 
consistent eclosure rate of slprBS06 males provided a measurable way to look for modifiers of the 
JNK signal.  At this point, there are approximately four small regions of the chromosome which 
interact with slprBS06 and are ready to be further dissected.  Identifying the gene and how it 
functions in JNK signaling will be exciting future work and may lead to characterization of 
unknown proteins and /or pathway associations.   
2.5 MATERIALS AND METHODS 
 
Fly stocks:   
Deficiency stocks were ordered from the Bloomington Stock Center or borrowed from the 
Campbell lab at the University of Pittsburgh.  Src42A alleles were obtained from the lab of 
Brooke McCartney at Carnegie Mellon University.   
 
 
 
Crosses:  
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Preliminary screening was done using two separate crosses of w,slprBS06/FM7i females and Df 
(2) / balancer males and incubated at 25°C.  Vials were flipped one time and progeny were 
scored.  w,slprBS06 ; Df(2) males were counted as a percentage against FM7i; Df(2) males.  All 
other progeny were scored as well.  GMR-Rac crosses were raised at 2C and scored based upon 
visual phenotypes comparing crosses to W1118 and other members of the JNK pathway.  
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3.0  CHAPTER 3:  EXPLORING THE ROLE OF MSN AS AN ACTIVATOR OF 
SLPR DURING DORSAL CLOSURE 
3.1 BACKGROUND AND SIGNIFICANCE 
Because of the many essential roles of the JNK pathway throughout development, understanding 
the unique set of activation signals and component interactions during each event is imperative.  
Specificity is likely influenced through distinctive sets of protein-protein interactions, including 
multiple upstream activators and variable protein complexes.  Currently, it is not clear what 
signals stimulate JNK activity in the leading edge cells during dorsal closure. The molecules 
which directly activate Slpr to elicit JNK activity, or modifiers of this pathway, either directly or 
through feedback mechanisms are also largely unknown.  This project takes a candidate 
approach by testing a specific molecule with ties to both JNK signaling and dorsal closure.   
3.1.1 Misshapen 
One candidate for Slpr activation is Misshapen (Msn), an Ste20-like kinase shown to bind to 
Dock, an SH3/SH2 adaptor protein.  In mammals, Msn’s homolog NIK, binds to the homolog of 
Slpr[16-18, 54].  Genetic evidence also indicates an involvement of Msn in dorsal closure, and 
this has been shown to operate through the JNK pathway[16-18, 53, 54].  Double heterozygous 
mutants of msn and bsk or hep show an increased number of dorsal open cuticles[53].  Msn is 
hypothesized to act as the JNKKK kinase upstream of Slpr, however, a direct connection has yet 
to be elucidated.  Here we began to test Msn’s ability to bind to and ultimately activate Slpr.   
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Figure 6: Msn protein structure. 
The middle proline-rich region has been shown to bind to Dock in eye development and is 
hypothesized to bind to the SH3 domain of Slpr during dorsal closure. 
 
 
3.1.2 Msn structure 
Msn has three domains: a kinase domain on the N-terminus, a regulatory domain on the C-
terminus and a middle region rich in PXXP motifs.  It is hypothesized that the middle proline-
rich region of Msn binds to Slpr.  In developing eye discs, the 447 amino acid region, termed 
here as MsnM, binds to the SH3 regions of Dock[17].  A GST-tagged form of MsnM was used in 
pull-down assays with Slpr; specifically, a 6xHIS-tagged form of Slpr comprised solely of the 
SH3 region at the N-terminus was used (a.a.1-114).  Two other HIS-tagged constructs of Slpr 
exist; one with the SH3 and the kinase domain, and another including the LZ/CRIB domains as 
well.  Bacterial expression of the larger constructs yielded insoluble protein so the HIS-SH3 was 
the only construct used in the pull-down assays described here. 
 Notably evidence supports a role for the C-terminal portion of Msn in dorsal closure; 
moreover, expression of Msn lacking amino acids 332-667 (the middle region) was able to 
almost fully rescue mutant embryos to the pupal stage, indicating that this region is not necessary 
for dorsal closure[18].  Still, it may play a role in binding Slpr within the full length protein.   
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Figure 7:  Constructs used in pull-down assays.   
Three forms of Slpr are 6x-HIS tagged, and three constructs are GST-tagged Msn proteins.  The 
SH3 portion was tested here for its ability to bind to GST-msnM. 
 
 
3.1.3 Hypothesis: The middle proline-rich region of Misshapen binds to the SH3 domain 
of Slpr to act as the JNKKKK during dorsal closure.   
3.2 PULL-DOWNS 
Pull-down experiments were done utilizing both the HIS and GST tagged forms of the proteins 
expressed in bacterial extracts.  Lysate of one protein was put on either the nickel column (HIS-
SH3) or glutathione agarose beads (GST-msnM).  The alternate protein was then tested for its 
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ability to bind.  Proteins were then eluted or boiled in sample loading buffer and separated by 
SDS-PAGE.  Gels were stained with Coomassie Brilliant Blue and analyzed for bound protein.   
 
 
 
 
 
 
 
 
Figure 8: GST pull-down.   
Purified GST-msnM was put onto glutathione agarose beads and purified HIS-SH3 was tested 
for its ability to bind.  HIS-SH3 was also tested for its ability to bind to the beads or to GST 
alone.  Because both proteins were purified and left in elution buffer, they do not stick to their 
respective columns. Most, if not all, loaded protein ran off the beads as seen in the flow through 
(first two lanes) and HIS-SH3 is not seen in any eluted fractions.   
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3.2.1 Results 
The results of the first pull-down experiment are shown in Figure 7.  The GST-msnM protein 
was bound to glutathione agarose beads and excess was washed off.  HIS-SH3 was then mixed 
with the beads and washed before all protein was eluted from the beads.  Controls include both 
proteins alone mixed with the beads and SH3 and GST alone.  The eluates show no binding 
between GST-msnM and HIS-SH3.  The elution fractions show low levels of GST-msnM.  It is 
comparable to the amount seen in the flow-through fraction which was originally put on the 
beads.  Reasons for this will be discussed below.  
Clearly, the results are difficult to distinguish.  Analysis of this original trial revealed 
problems with the buffers used and the set-up of the experiment itself.  
3.2.2 Problems 
The problem with the experiment shown in Figure 7 has to do with the state of the proteins used.  
In this case, both proteins used in the pull-down assay were purified; the HIS-SH3 on the nickel 
column and the GST-msnM on the glutathione agarose beads.  Both were then eluted from their 
respective columns and used in the pull-down experiment.  This posed a problem for two 
reasons.  First, because the GST-msnM was in elution buffer, this made it very difficult if not 
impossible to stick to the beads.  Second, the HIS-SH3 was also in elution buffer containing 
imidizole and would not have stuck to the nickel column if a nickel column pull-down was 
attempted.   
 In order to fix this problem, bacterial lysates were initially put on the respective columns 
and purified protein was tested for binding (see Figures 8 and 9).   
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Figure 9:   Nickel column pull-down.   
HIS-SH3 lysate was put on the nickel column and purified GST-msnM was tested for binding.  
LY: bacterial lysate expressing HIS-SH3; IP: amount of purified GST-msnM input on column; 
E: elution fractions.  The last three lanes show HIS-SH3 eluted from the column alone, a lack of 
GST-msnM being eluted from the nickel column, and both proteins present in the elution when 
both proteins were put on the same column together.  Excess proteins are also visible in the 
elution lanes containing HIS-SH3. 
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Figure 10:  GST-pull down.   
GST-msnM lysate was put on glutathione agarose beads and purified HIS-SH3 was tested for 
binding.  LY: bacteria lysate expressing GST-msnM; IP: input of purified HIS-SH3; E: elution 
fraction; B: beads were boiled to release all bound proteins.   The GST eluate shows that no HIS-
SH3 bound to the GST alone.  In the boiled fractions, GST-msnM is clearly seen at approx. 
80kD, but no SH3 is present in any eluate.   
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3.2.3 Results 
The results shown in Figure 8 and Figure 9 were done using original bacterial lysates expressing 
either GST-msnM or HIS-SH3.  Purified HIS-SH3 or GST-msnM were then added to each 
bound protein and tested for their ability to bind.  Again, when the GST-column was used, no 
HIS-SH3 was detected in any boiled fraction indicating a lack of binding.  However, when HIS-
SH3 was bound to the nickel column, GST-msnM was able to bind and was seen in the eluate 
only when HIS-SH3 was present.  Together, both pull-downs seem to give ambiguous results; 
however, it is clear that only the protein with the correct tag binds to its respective column.  It is 
possible that the tags caused differences in folding severe enough to change the binding 
properties.  Still, the purified proteins used were not dialyzed into more physiological buffers 
from the elution buffers in which they were purified.  To be confident of binding, this step would 
be necessary.  Also, the amount of protein originally loaded on each column should be 
quantified.   
3.2.4 Controls 
Before attempting to repeat the pull-down experiments, I generated additional controls.  Since 
earlier analysis had shown the SH3 regions of Dock bound the middle region of Msn, the Dock 
cDNA was obtained and its SH3 domains were PCR amplified and cloned into the HIS-tag pET 
vector to use as a positive control.  Also, the N- (a.a. 1-317) and C-terminal (a.a. 763-1102) 
regions of the Msn protein may serve as negative controls to show specificity for amino acids 
321-768 and/or binding to these other regions. 
The first attempts at generating the other Msn constructs were done using RT-PCR on 
mRNA from embryos. The primers annealed to another region of homology in the mRNA pool 
and amplified a different gene instead of the C-terminus of Msn.  Furthermore, the N-terminal 
portion was difficult to PCR amplify at all.  Eventually, the msn cDNA was acquired from the 
Treisman lab  at the Skirball Institute of Biomolecular Medicine [18, 53] and PCR was done to 
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amplify the regions of interest.  These were cloned into the pGEX 4T-1 vector to generate an N-
terminal GST tag. The C-terminal portion of Msn (called GST-msnC) was tested by cutting at 
restriction sites engineered in the primers.  Induction with IPTG led to expression of protein of 
the correct size (approx. 66kD).  Induction of GST-msnC produced large amounts of protein, but 
it was highly insoluble.  Treatment with 8M urea was unsuccessful to solubilize the protein.  
Induction of potential N-terminus (called GST-msnN) clones revealed a 26kD expressed protein, 
the size of GST alone suggesting an early termination of the protein or a frame shift introduced 
during cloning.  Sequencing reactions were not conclusive thus far.     
As steps were taken to use the two new controls, GST-msnC and HIS-Dock, GST-msnM 
ceased to be expressed as before and so the cDNA was used to generate a new construct as well, 
in order to ensure the correct protein was engineered and tested.  Now we wonder whether the 
cDNA is questionable.  For now, these constructs need to be verified through sequence analysis 
and protein induction, then solubility can be refined.  The cDNA must be reanalyzed and the 
sequences of all constructs verified before further binding experiments can take place.   
3.2.5 Conclusions 
Pull-down experiments using various tagged forms of proteins are common experiments done in 
the lab to show an interaction between two proteins.  The experiments completed so far show 
that it is feasible to use this procedure to check for binding between Slpr and Msn.  Previous 
research has shown that SH3 domains often bind to PXXP motifs, and that this is true of Msn 
and Dock[17].  Therefore, we have made constructs including just the PXXP motifs of Msn and 
the C-terminal portion as a non-binding control.  The HIS-SH3 construct of Slpr expresses well 
in E. coli and is soluble.  Fortunately, most of the protein is easily bound to and eluted from a 
nickel column.  Also, the three SH3 domains of Dock, a positive control for Msn binding have 
been cloned and behave well during expression and purification.   
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3.3 FUTURE DIRECTIONS 
This assay is the first step to establishing if Msn is an upstream activator of Slpr.  Pull-downs are 
often done as initial experimentation assessing an interaction between two proteins.  In this case, 
although the hypothesis suggests binding between the middle region of Msn and the SH3 domain 
of Slpr, it is possible that this may not be the case.  According to genetic rescue experiments, the 
C-terminal portion of Msn seems to be necessary for rescue of a mutant phenotype and therefore 
may be necessary for binding as well.  The other constructs described here will be able to test for 
binding of all parts of Msn, albeit separately.  A full length, tagged construct can be prepared and 
tested as well.  The ultimate goal is to identify Msn as an activator of Slpr.  This, obviously, will 
require at least the kinase domain, if not the full-length protein to be used in activation assays.   
3.3.1.1 Pull-downs 
 
Future directions begin with authenticating each of the Msn constructs in the pGEX plasmid.  
Sequencing and protein induction tests will confirm the correct sequence and protein size.  
Protein will then need to be solubilized and tested individually for the ability to bind to 
glutathione agarose beads.  Once each of the constructs are confirmed, purified samples of each 
Msn construct, the HIS-Dock and HIS-SH3 proteins will be made.  Critically, each protein will 
need to be dialyzed into a neutral buffer so that it can be used for binding in the opposing assay. 
Once these steps are completed, the pull-down assays can be completed as described in 
the experimental methods section.  Briefly, GST-tagged protein lysates can be loaded on 
glutathione agarose beads, rinsed and then purified HIS-SH3 or HIS-Dock can be loaded over 
top.  The beads can then be rinsed and boiled, lysates separated by SDS-PAGE and stained with 
Coomassie.  Subsequently, proteins could be identified by Western blot.  Also, HIS-tagged 
protein lysates can be bound to nickel columns and rinsed.  GST-tagged purified proteins can 
then each be run individually over the columns, rinsed, and finally eluted with 100mM imidizole.  
Proteins will be identified after running on a gel.  Western blotting will be critical to positively 
identify proteins eluted from the columns or beads. 
 Similarly, both proteins can be incubated together first, then run over the respective 
columns and eluted or boiled.  Although purifying the proteins is recommended, it would be 
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possible to use lysates of both proteins in each assay and may be necessary if other molecules or 
scaffolding proteins are necessary to facilitate binding.  Full length constructs of both proteins 
can be made as well, should binding be absent in all cases.  To overcome the problem of 
purifying insoluble tagged proteins, they can be in vitro transcribed and translated incorporating 
radioactive methionine to label the protein.  Here, only the radiolabelled protein would be visible 
using a phosphoimager, indicating its ability to bind to the protein on the column.  Western 
blotting could be used to identify all significant proteins present. 
3.3.1.2  Kinase Assays 
 
The vital follow-up experiment to the binding assay is a kinase assay testing the ability of Msn to 
activate Slpr as a phosphorylation substrate.   Most likely, the N-terminal kinase domain 
construct (GST-msnN) would be tested for it’s ability to phosphorylate Slpr.  A full-length Msn 
protein should also be engineered in order to test Slpr activation. The two longer HIS-tagged 
forms of Slpr could be utilized, as well as a full-length construct.  In vitro 
transcription/translation and phosphatase assays, as well as [32P]-labeled ATP could test for the 
transfer of phosphate groups to Slpr, and such protocols are being currently developed in the lab.  
3.4 MSN PHENOTYPES 
A second way to test for a relationship between Msn and Slpr is through genetic studies.  
Previous data have indicated an interaction between the JNK pathway and Msn in the 
embryo[18, 53].  Genetic data has linked Msn to the JNK pathway during dorsal closure, but 
Msn has not been shown to interact genetically with Slpr thus far.  Cuticle preps of msn mutant 
embryos have revealed obvious holes in the dorsal side of the embryo[18, 53].  In order to relate 
Msn’s role in dorsal closure to Slpr-specific JNK signaling, we set out to look for genetic 
interactions between the two genes.   
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3.4.1 Embryonic Viability Screen 
It has been shown that heterozygous msn mutants have no or weak dorsal open phenotypes but 
homozygous msn mutants and transheterozygous msn and bsk mutants exhibit holes in the dorsal 
side of the cuticle[53].  In order to repeat these results and to test for this phenotypic interaction 
with slpr mutants, crosses between multiple msn mutants and mutant alleles of bsk and slpr were 
set up.  Embryo viability and cuticle phenotypes were scored.    
3.4.1.1  Experimental Approach 
 
slprBS06 heterozygous flies were crossed to bsk2 and msnJIE2, msn172 and msn102 heterozygous 
mutant flies.  Embryonic lethality was scored and cuticles of dead embryos were analyzed for the 
presence and severity of dorsal holes.  msnJIE2  is a recessive allele harboring a P-element 
insertion and msn172 and msn102 are viable inversion mutant alleles[52].  bsk2 is a dominant EMS 
mutant.  Doubly heterozygous progeny were expected to show an increase in percent lethality 
and number of dorsal open cuticles.  If Msn is involved in dorsal closure mediated by Slpr 
signaling then doubly heterozygous progeny (slpr/+;msn/+) are expected to show an increase in 
lethality and phenotypic severity.   
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Figure 11:  Embryonic viability results. 
Heterozygous mutants of msn or bsk were crossed to both wild-type (W1118) and slprBS06 
heterozygous mutants.  Embryos were lined up and dead embryos were scored as a percentage 
against the total amount of fertilized embryos.  Except for msn102, lethality does not seem to be 
significantly affected by having both msn and slpr mutations.  
 
 
3.4.1.2 Results 
 
msn102 was the only allele with any change, having 33% lethality when crossed to slprBS06 
compared to 17.2% lethality when crossed to W1118.  The other alleles of msn and bsk had 
approximately the same percentage as wild-type.   
When cuticles were scored, the amount of embryos scored possessing dorsal holes was 
unusually high (compared to Su et al. (1998) and other Stronach lab data).  This could be a result 
of phenotypes which were difficult to score, and possibly a problem with the environment of 
embryos before analysis.   
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3.4.2 Transgenics 
Genomic insertions of Slpr wild-type (slprwt801), a kinase-dead from of Slpr (slprkd13) and wild 
type Msn (msn) exist with Gal4 Upstream Activating Sequences (UAS).  Recombinant lines 
were made harboring two transgenes, UAS-slprwt801 and UAS-msn (UAS-slprwt801, UAS-msn), and 
also UAS-slprkd13 and UAS-msn (UAS-slprkd13, UAS-msn) transgenes.  These lines, as well as the 
individual UAS lines, were then crossed to various Gal4 drivers in order to look for phenotypic 
differences during protein overexpression.  It was hypothesized that phenotypes observed with 
the wild-type slpr transgene would be exacerbated with the UAS-msn present.  In addition, 
phenotypic observations were hypothesized to provide more specific information on the 
relationship between the two proteins.  
 
 
3.4.2.1 Experimental Approaches 
 
The approach discussed here looked at phenotypes of the five different transgenic lines: (1) UAS-
msn, (2) UAS-slprwt801, (3) UAS-slprkd13, (4) UAS-msn, UAS-slprwt801, and (5) UAS-msn, UAS-
slprkd13.  These were all crossed to either pnrGal4 or pnrGal4, pucE69 flies.  pnrGal4 drives 
expression of the UAS constructs in the pannier domain around the dorsal side of the embryo 
and developing adult thorax.  pucE69 is a P-element insertion disrupting puc and harboring a LacZ 
reporter[45]; therefore, the negative feedback mechanism is disturbed and the JNK signal cannot 
be down-regulated through Puc’s phosphatase activity.  Moreover, we could assess the extent of 
JNK signaling in the leading edge in the embryo using  
Puc as a readout.  The adults that eclose from the cross could also be analyzed for phenotypic 
consequences.  Both sets of crosses were incubated at 18°C and 22°C as the Gal4/UAS system is 
temperature sensitive, eliciting more protein production at higher temperatures. 
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Figure 12:  Phenotypes of pnrGal4 at 22°C. 
UAS lines were crossed to pnrGal4/TM3,Ser,UASy+ and raised at 22°C.  Thorax phenotypes 
were observed.  UAS-slprwt801 expression causes a narrowed scutellum.  Doubled bristles are also 
seen on the scutellum of UAS-slprkd13 flies (arrow).  However, Msn and Slpr coexpression does 
not lead to an increase in phenotypic severity suggestive of increased JNK signaling.  Since 
UAS-msn alone did not give a phenotype, it was difficult to assess whether coexpression of UAS-
slprkd13 blocked it.   
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Figure 13:  Slpr and Msn overexpression phenotypes.   
UAS flies were crossed to pnrGal4,puce69 and raised at 22°C.  Thorax phenotypes were 
examined, special notice given to width, number of bristles and size of scutellum.  Phenotypes 
were more severe at 22°C.  UAS-slprwt801, with or without UAS-msn showed severe cleft thoraces 
and loss of the scutellum.  No phenotype was seen with UAS-msn alone.   
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 3.4.2.2 Results:  Phenotypes of recombinants  
 
 
At 18°C, there was no significant effect on thorax phenotype when all five transformant lines 
were crossed to pnrGal4 flies (not shown).  UAS-slprwt801 and UAS-slprwt801,UAS-msn flies 
crossed to pnrGal4, pucE96 at 18°C showed a highly reproducible severe cleft thorax, and usually 
loss of the scutellum.  Bristles were shortened, kinked or sometimes doubled.  As seen in Figure 
10, at 22°C, UAS-slprwt801 flies showed thinner, more compact thoraces, with a more pointed 
scutellum when crossed to pnrGal4 flies.  UAS-slprkd13 and UAS-slprkd13,UAS-msn thoraces were 
slightly wider, often with doubled bristles on the side of the scutellum.  UAS-slprwt801 and UAS-
slprwt801,UAS-msn crosses with pnrGal4,pucE69 crosses at 22°C showed a severe thorax 
phenotype as well.  It did not appear as though the addition of UAS-msn affected the phenotype 
of the slprwt801 alone.  Notably, no phenotypes were seen when UAS-msn was crossed to either 
Gal4 driver, at either temperature, indicating no effect of overexpression of the protein in the pnr 
domain, or a lack of expression of the Msn protein.  Also interesting was the lack of UAS-slprkd13 
strong phenotypes.   
 
3.4.3 Conclusions 
The UAS-slpr constructs (both wt801 and kd13) showed defects in thorax closure.  The kinase 
dead construct did not show very severe phenotypes, which is interesting because the 921 allele 
of slpr, which is also a kinase dead form, shows very early lethality.  However, there may be 
enough wild-type slpr in these transgenic flies to make it through to adulthood.  Unfortunately, 
UAS-msn did not show any phenotypes, either alone or in combination with the UAS-slpr 
constructs.  A new stock harboring the UAS-msn transgene was ordered from the Bloomington 
Stock Center to check for activity, in the chance that our stock had changed, or was not as we 
had thought it to be.  This transgene was mapped to the third chromosome (though it was 
annotated as mapping to the second chromosome) by following an eye color selectable marker.  
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Crosses to Gal4 drivers such as apterousGal4 and actinGal4 did show slight phenotypes (see 
Figure 12) suggesting that the transgene was being expressed.  Therefore, the phenotypic studies 
using the UAS-msn construct should be repeated.  New recombinants between UAS-slprwt801 or 
UAS-slprKD13 should also be made with the new UAS-msn line. 
 
 
 
Figure 14:  Phenotypes of UAS-msn.   
When the new stock of UAS-msn was crossed to various Gal4 drivers, some phenotypes were 
observed.  actinGal4 caused a genital rotation phenotype and a slight narrowing of the thorax.  
Similar phenotypes are observed in slpr mutants.  apterousGal4 caused a severe shortening of 
the scutellum.  
 
3.5 FUTURE DIRECTIONS 
Future studies should include re-engineering the recombinant Msn/Slpr lines and observing any 
overexpression phenotypes.  Lethality screening and cuticle observations should also be repeated 
for consistency and correct identification of dorsal open phenotypes.  Another approach which 
can quickly be done to look at JNK activity in embryos during dorsal closure is 
immunofluorescence.  The same transgenic lines used in the phenotypic experiments should be 
crossed to pnrGal4,pucE69.  Embryos can then be collected, washed and immunostained with 
antibodies against ß-gal and phospho-tyrosine, a general cell membrane marker.  pucE69 harbors 
a LacZ reporter and is a consistent readout of JNK pathway activity.  Loss or expansion of 
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pucLacZ may be predicted if coexpression of Msn and Slpr changes the balance of JNK 
signaling negatively or positively.   
 Also, transgenic lines were recently made to express UAS-SH3-HA and UAS-LZCRIB-
HA.  Phenotypic analysis of the individual lines should be completed, as well as with 
recombinants made between these new lines and the UAS-msn line.  Antibodies against the HA 
tag can be used to look for protein expression and localization.   
 
3.6 MATERIALS AND METHODS 
 
Pull-downs:  
GST-pull-downs were done using approximately 100uL glutathione agarose beads (Sigma 4510).  
Approx. 1 mL GST-msnM protein lysate or purified HIS-SH3 was put on the beads and 
incubated with rocking at 4°C for one hour.  Each tube was washed with 500uL PBT 10 minutes 
at 4°C with rocking, spun down 2 minutes at 2000rpm.  To the GST-msnM containing tube, 1 
mL purified HIS-SH3 was added and incubated one hour at 4°C with rocking.  The tubes were 
washed again with PBT and eluted with 100uL elution buffer (5mM reduced glutathione in 
50mM Tris-HCl, pH 9.5) for 15 minutes.  Boiled elutions were obtained by adding 100uL 2X 
SDS buffer and boiled at 95°C for 2 minutes.   
  Nickel-column pull-downs were done under native conditions according to protocols by 
Qiagen.  600uL of purified GST-msnM was added after the second wash step and spun according 
to protocol.  Two more washes were done and then eluted as described.   
 
Lethality Screens and Cuticle preps: 
w,slprBS06/FM7i,GFP females were crossed to w;msn172,FRT80/+, w;msn102/+ , 
yw;p(w+msnJ1E2)/+, bsk2 cn1 bw1 sp1/+ or W1118 males and incubated at 25°C in cages 
overnight.  125-225 embryos were collected and lined up on apple juice plates and incubated at 
25°C overnight.  After 24hrs, unhatched embryos were counted and then scored as fertilized or 
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unfertilized.  The total fertilized but unhatched number was recorded as a percentage over total 
fertilized.   
Cuticles were processed from brown, fertilized but unhatched embryos by fixing in acetic 
acid:glycerin (4:1) for 30 minutes at 60°C and then holding at RT for at least 24 hours.  The 4:1 
solution was then replaced with CMCP-10 mounting media:lactic acid (3:1) and placed on a 
slide.  The slides were then incubated on a slide warmer (~ 50° C) overnight.  Dark field 
microscopy was used to view cuticles and embryos were scored for the lack or presence of mild, 
or severe dorsal holes.   
 
 
Cloning: 
UAS-slprSH3-HA and UAS-slprLZ/CRIB-HA:  The SH3 domain of Slpr and the LZ/CRIB 
portions of Slpr were amplified by PCR (primers are listed in Appendix A) and cloned into the 
pGEM-T Easy vector (Promega).  Each PCR construct was then digested out of pGEM-T Easy 
using Kpn1 and EcoRI restriction sites and ligated into a pBS(SK+) vector containing a C-
terminal 2x HA-tag (obtained from the lab of Gerard Campbell, University of Pittsburgh).  The 
SH3-HA and LZ/CRIB-HA tagged constructs were digested from pBS-HA and ligated into 
pUASp using Kpn1 and Not1 restriction sites.   
HIS-Dock:  Dock cDNA LD42588 was ordered from DGRC.  The three SH3 regions of Dock 
were PCR amplified and ligated into pET16b (Novagen) to add an N-terminal 6xHIS-tag.   
GST-msnN and GST-msnC:  mRNA from W1118 embryo lysates was originally used to amplify 
the N- and C-terminal portions of Msn by RT-PCR.  The msn cDNA was also obtained from the 
lab of Jessica Treisman (New York University Medical Center) and used as a template to PCR 
amplify both constructs.  PCR products were ligated into pGEX-4T-1 (Amersham).   
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4.0  CHAPTER 4: CONCLUSIONS 
4.1 DEFICIENCY SCREEN  
In an attempt to efficiently screen the entire genome of Drosophila for modifiers of Slpr-
mediated JNK signaling, a deficiency “kit” was used to check the entire second chromosome.  
The large deleted regions, although harboring many genes, covered the majority of the second 
chromosome.  By reducing the dosage of genes using the deficiencies, it was possible to look for 
modifiers of JNK signaling.  The normally consistent viability phenotype of the BS06 allele 
became a malleable readout of JNK activity.  Some problems were evident involving percentage 
consistency and phenotypic observation.  It was very important to set up multiple crosses and to 
thoroughly research the chromosomal markers for each deficiency stock.  Crosses that produced 
unexpected progeny due to recombination or nondisjunctions were discarded.  Eventually some 
stocks showed consistent results and were analyzed to determine breakpoints.  The genes within 
the noted regions were also analyzed in order to find smaller deficiencies as well as alleles of 
putative interactors.   
Deficiencies are becoming more popular in their value as genetic tools.  Consequently, 
deficiencies exist from Bloomington (which are used here) and are updated frequently.  Also, 
there is a collection from Harvard (Exelixis) which can be used to find smaller deletions.  If there 
is a gene which shows promise as a strong candidate, then alleles of that gene can also be 
obtained and tested, as was done with the src42A alleles.  Unfortunately, neither src42A allele 
modified the slprBS06 mutant.  Also, although it is possible to get no BS06 males (0%) after 
setting up many crosses, indicating the presence of an enhancer, the ability to pull out 
suppressors is more efficient.   
In order to substantiate the effect seen in the deficiency screen, we performed a 
secondary assay which enhanced or suppressed the level of JNK signaling.  For our screening 
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purposes, the ease of the assay was beneficial, and because all of the members of the pathway 
acted accordingly, it was with confidence that this phenotype was legitimately used to check for 
validity of our original screen.  Nonetheless, because the molecular interactions which cause the 
eye to have a rough appearance are not understood, it is possible that a modifier of BS06 lethality 
may not have acted as expected.  Therefore, results should be interpreted with caution, especially 
when looking at specific mutant alleles.  One important experimental note is to carefully use 
comparative analysis when using the GMR-Rac assay.  Control crosses should always include 
wild-type and known enhancers and suppressors of the eye phenotype in order to compare the 
unknown interactor.  Phenotypes are somewhat variable and must be scored as an average of all 
progeny.   
The results of both screens have led to identification of five deficiency stocks which 
show enhancement or suppression of JNK signaling.  Two of these show consistent results in 
both assays.  Future work would include obtaining smaller deficiency lines to further narrow 
down the region where the gene resides, and testing specific alleles of predicted modifiers.  The 
two stocks which show varying results between the two screens should be retested in both assays 
and analyzed further.   
The prospect of finding possibly four genes which may play some role in the specificity 
of signaling through the JNK pathway is exciting.  However, it is very possible that one of the 
many uncharacterized genes within the regions of interest may be influencing JNK signaling.  
Further work will be needed to identify and characterize the involvement of any molecules and 
to provide the link to Slpr-mediated JNK signaling.   
4.2 MISSHAPEN 
In addition to looking for modifiers of the pathway, this work also set out to identify upstream 
signaling components involved in dorsal closure.  By taking a candidate approach, the ability to 
test directly for binding and activation was fairly straightforward.  Although the conclusions 
drawn here cannot say with certainty whether Msn is the JNKKKK acting on Slpr, progress has 
been made in order to reach that goal.   
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Based on the hypothesis that Msn is the upstream activator of Slpr, we tested for 
interactions using pull-down assays with bacterially expressed proteins.  Although initial 
attempts proved inefficient, they were cause for reevaluation of buffer conditions, controls and 
overall experimental design.  The constructs which are currently being tested in the lab include 
GST-tagged forms of Msn; the middle proline-rich region as well as both termini, and two HIS-
tagged constructs; one is the SH3 domain of Slpr and one is the SH3 domains of Dock (which 
have previously been shown to bind to GST-msnM).  Some of these are ready to be used, and 
others are still being verified. 
Because of the intriguing genetic studies using portions of Msn, it will be interesting to 
see how binding is achieved and through what portions of the protein this is accomplished (if 
binding is actually taking place).  Kinase assays will further establish whether Msn is an 
upstream component of the JNK pathway and an activator of Slpr.   
The genetic analysis presented here were also useful to test for phenotypic detection of 
overexpressional analysis in vivo.  In order to retest and feel confident in the outcome, the new 
UAS-msn stock should be used to make new recombinant lines and retested in the pnrGal4 and 
pnrGal4pucE69 expression crosses.  However, it was clear that UAS-slprwt801 and UAS-slprkd13 
showed some type of thorax developmental defects, related to the defects seen in Mlk3 -/- mice 
midline phenotypes.  Testing the ability of UAS-msn to affect these phenotypes should further 
the data regarding Msn’s effect on JNK signaling.  The phenotypes seen with the new UAS-msn 
transgenic line are interesting and open the door to further research, especially considering the 
genital rotation defect observed in approximately 5% of the male progeny when expressed using 
the apGal4 driver.  This is the same phenotype seen in slprBS06 mutants and with mutant Pvf1/Pvr 
ligand/receptor complexes.   
4.3 CONCLUSION 
Overall this work was directed at identifying molecules that influence Slpr-mediated JNK 
signaling, specifically those that affect the process of dorsal closure.  It has narrowed down four 
regions of chromosome two which likely encompass enhancers or suppressors of the pathway.  
Additional assays are necessary to examine protein-protein interactions between Slpr and Msn, 
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which have previously been implicated through genetic experiments.  Further phenotypic 
analysis can be used to explain the role of Msn as a stimulant of the pathway and may lead to an 
understanding conditions which lead to activation of JNK signaling, specifically the conditions 
necessary for dorsal closure to occur.   
This is just one pathway which affects a small number of processes during embryo 
development.  But understanding this sequence of events can provide volumes about cell 
signaling in all types of processes.  The specificity required for correct, robust cellular responses 
is embedded in the network of protein-protein interactions and the intersection of molecules 
between pathways, cells, and tissues.  It is the hope that further work on this project may 
eventually lead to medical contributions for those affected with developmental and wound 
healing defects.   
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APPENDIX A 
PRIMERS USED FOR CLONING 
Construct            Primer Name  Restriction Site  Primer Sequence (5’- 3’) 
UAS-SH3-HA  CRSH3f Kpn1      GGATGGGGTACCCCCAACATGCTG  
   CRSH3R EcoR1    GATGTCGCCGAATTCGGACGAGAC  
 
UAS-LZCRIB-HA  CRLZf      Kpn1      GCCCGGGGTACCCCTTCACTACATG 
   CRCRIBr EcoR1    GATGCGGAATTCGGAGAAGGAAGG   
 
HIS-Dock  dockSH3FBam   BamHI  CACAGGATCCGGGCAACATGAAGCAC 
  DOCKSH3ref     BamHI GATCGGATCCGCACTGGCACTCGCATTACG 
 
GST-msnN  MSN Nfor EcoRI    GATCGAATTCATGGCGCACCAGCAGCAAC 
   MSN Nrev XhoI    GATCCTCGAGATAGTCCTCGCGCTCCTTC 
 
GST-msnC  MSN Cfor EcoRI    GATCGAATTCACCTCCCACGAGGCGGCC 
   MSN Crev XhoI    GATCCTCGAGTTACCAATTGGCCATGC 
 
GST-msnM  MsnMRev     XhoI      CGTACTCGAGGAGGTGGGCGTTACATTGACA 
   NEWMsnMFor   EcoRI   GATCGAATTCCAGGAGAAGGAGCGCGAG 
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APPENDIX B 
PLASMID MAPS 
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LZCRIB with HA in UASp.txt
11962 bp
HindIII - 47
XmnI - 550
XmnI - 600
EcoRV - 1754
XmnI - 1998
SacI - 2871
EcoRV - 4651
XhoI - 4835
HindIII - 4847
HindIII - 5203
XbaI - 5436
HindIII - 5443
XhoI - 5457
KpnI - 5496
SapI - 5581
EcoRV - 5764
EcoRI - 5844
EcoRV - 5895
XbaI - 5925
NotI 5932
BamHI - 6002
EcoRI - 6252
XbaI - 6698
BamHI - 6704
BsaI - 7260
XhoI - 7558
SacI - 8355
SacI - 8763
SapI - 8843
HindIII - 8964
XmnI - 10296
BsaI - 10830
LZCRIB-HA UA
S
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 SH3-HA in pUASp
11955 bp
HindIII - 39
XmnI - 542
XmnI - 592
EcoRV - 1746
XmnI - 1990
SacI - 2863
EcoRV - 4643
XhoI - 4827
HindIII - 4839
HindIII - 5195
XbaI - 5428
HindIII - 5435
XhoI - 5449
KpnI - 5488
XbaI - 5594
BsaI - 5601
EcoRI - 5835
XbaI - 5918
NotI 5925
BamHI - 5995
EcoRI - 6245
XbaI - 6691
BamHI - 6697
BsaI - 7253
XhoI - 7551
SacI - 8348
SacI - 8756
SapI - 8836
HindIII - 8957
XmnI - 10289
BsaI - 10823
SH3-HA UA
S
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